Test Price
1,200 AED✅ Home Collection Available
JAK2 Mutation Detection Panel (Exons 12-15) – Comprehensive Genetic Test in Dubai
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing using gold‑standard Sanger sequencing of exons 12–15.
- Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post‑test clinical guidance provided by a consultant medical geneticist for expert interpretation of your results.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test uses Sanger sequencing to analyse exons 12–15 of the JAK2 gene, identifying mutations that drive Philadelphia‑negative myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The comprehensive panel detects all exon 12–15 variants, including rare mutations missed by allele‑specific PCR targeting only the V617F hotspot.
| Feature | Our Test (Sanger Sequencing) | Alternative (JAK2 V617F PCR Only) |
|---|---|---|
| Methodology | Gold‑standard Sanger sequencing of exons 12–15 | Allele‑specific PCR (V617F only) |
| Detection Scope | All exon 12–15 mutations, including rarer variants such as K539L, N542‑E543del, and F537‑I546dup | Only the JAK2 V617F mutation; misses exon‑12 and other exon 13‑15 abnormalities |
| Diagnostic Sensitivity | >99.9% for targeted region | ~97% for V617F, but false‑negative for other mutations |
| Turnaround Time | 7–8 working days | 3–5 working days |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), Consultant Medical Genetics, notes: “The JAK2 exon 12‑15 panel provides the highest possible resolution for confirming a myeloproliferative neoplasm diagnosis. Identifying the exact mutation allows your haematologist to tailor therapy more precisely, but results must always be correlated with full blood counts and clinical presentation. We ensure every patient receives a dedicated post‑test telephone discussion to explain the implications in plain language.”
Advisory Notice
Do not discontinue any prescribed medication, especially anti‑coagulants or cytoreductive therapy, without consulting your treating physician. This test is a diagnostic aid and does not replace urgent clinical evaluation if you experience symptoms of thrombosis or haemorrhage.
Safety Exclusion Criteria & Emergency Red Flags
- Home collection is not performed on patients with unstable vital signs, active severe bleeding, platelet count <20,000/µL, or uncontrolled coagulopathy without prior medical clearance.
- Bone marrow aspiration (if required) is a hospital‑only procedure performed under local anaesthetic after at least 6 hours of fasting. Do not drive immediately afterwards.
- Seek immediate emergency care if you experience sudden severe headache, vision changes, chest pain, leg swelling, or signs of blood clots (deep vein thrombosis, pulmonary embolism).
Patient FAQ & Clinical Guidance
1. Why is the JAK2 exon 12‑15 panel preferred over a simple JAK2 V617F test?
The JAK2 V617F mutation accounts for about 95% of polycythemia vera cases, but up to 50% of essential thrombocythemia and primary myelofibrosis may harbour variant mutations in exons 12–15 that are invisible to standard allele‑specific PCR. Our Sanger sequencing ensures no hidden abnormality is missed, providing the most complete genetic profile for diagnostic certainty and evidence‑based management.
2. How should I prepare for the blood or bone marrow collection?
Peripheral blood collection requires no special preparation and can be performed during a home visit without dietary restrictions. If a bone marrow sample is needed (when peripheral blood is insufficient), your referring physician will coordinate the procedure; you will be asked to fast for at least 6 hours and a local anaesthetic will be used to minimise discomfort.
3. Does insurance cover the JAK2 mutation panel in the UAE?
Coverage depends on your policy and clinical indication. Most UAE insurance plans cover this panel with a valid prescription. Our insurance desk performs a pre‑authorisation check once you share your Emirates ID and prescription via WhatsApp. We support all major local networks and submit direct billing on your behalf. Contact us at +971 54 548 8731 to verify your coverage.
UAE Regulatory & Data Privacy Adherence
All patient data are processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our Dubai Healthcare City facility operates under DHA Facility Licence Number 1143 and maintains ISO 9001:2015 certification for quality management.
Clinical & Logistical Metadata
| Test Name | JAK2 Mutation Detection Panel (Exons 12-15) |
| Price (AED) | 1,200 AED |
| Turnaround Time | 7–8 working days |
| Sample Type / Matrix | Peripheral whole blood (preferred); bone marrow aspirate (hospital extraction only) |
| Methodology Used | Sanger sequencing of exons 12–15 |
| ICD-10-CM Code | D47.1, D45, D47.3, D47.4 |
| LOINC Code | 33953-9 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians